Shaanxi Dongke Pharmaceutical Co., Ltd. (hereinafter referred to as “Dongke Pharmaceutical”) is a pharmaceutical enterprise integrating R&D, production and sales. The registered capital is RMB.
Shaanxi Dongke Pharmaceutical Co., Ltd. is a pharmaceutical enterprise integrating research and development, production and sales (hereinafter referred to as “Dongke Pharmaceutical”). It was established in 1993 and established in Yangling in 1998. It is the first batch of key enterprises in Yangling. One. The companys total assets are nearly 900 million yuan and it has 350 employees. The company has seven dosage forms of capsules, granules, tablets, rubber pastes, powders, patches and ointments. There are 39 products covering respiratory, gynaecology, digestion, pediatrics, old age, orthopedics, cardiovascular and cerebrovascular diseases, and cancer. field.
Since its establishment, the company has won the honors of “Shaanxi Province Quality Credit A-level Enterprise”, “Shaanxi Province Safety Production Advanced Unit”, “Safe Production Standardization Level 3 Enterprise” and “Yangling Economic Development Outstanding Contribution Award”; “Huanglong Zhike Granules, Ganhai Weikang Capsule has been selected as “Shaanxi Famous Brand Product” for more than 10 years. The “Dongke” and “Yaowangshan” trademarks have been awarded the famous trademarks of Shaanxi Province, and their popularity and influence in the industry are increasing.
In 2014, Dongke Pharmaceutical and Jichuan Pharmaceutical Group carried out equity strategic cooperation and became a wholly-owned subsidiary of the group. Jichuan Pharmaceutical Group is located in Taizhou City, Yangtze River Delta. It was successfully listed on the Shanghai Stock Exchange in 2013 with stock code 600566. Now it is a state-level high-tech enterprise group integrating drug research and development, manufacturing and commercial circulation. The national Torch Plan is the backbone enterprise of Taizhou Pharmaceutical Industry Base, 34 of the countrys top 100 pharmaceutical companies, and the 5th most competitive pharmaceutical listed company in China. name.
The equity strategic cooperation between Jichuan Pharmaceutical Group and Dongke Pharmaceutical not only integrates the superior product resources, but also contributes positively to the poverty alleviation in the western region. It is a successful case for the old enterprises to build a new platform and a new mechanism for grafting old varieties. The new paradigm of economic and trade cooperation between the eastern and western enterprises has written a new chapter for the coordinated development of cross-regional industries.
In order to further expand production scale and increase production capacity, the company will be fully operational in the construction of “Yangling Pharmaceutical Production Base” covering an area of 300 mu in the Yangling Demonstration Zone in 2016. At that time, a modern pharmaceutical company with advanced equipment and beautiful factory facilities will stand in the market. Yangling Land has become a new business card for biomedical enterprises in Yangling Demonstration Zone.
Dongke Pharmaceutical adheres to the corporate mission of “defending health with technology”. Guided by the “Double Hundred” strategy of the Group, the company leverages the resource advantages and favorable policies of the Shaanxi Free Trade Zone and relies on the Groups funding platform, academic resources and marketing advantages. We will do a good job in safety production, continuously improve our management and management, and strive to be among the top pharmaceutical companies in Shaanxi Province, becoming an influential Chinese medicine boutique enterprise in the northwest region and even the whole country.